Drugs / Imeglimin
Imeglimin
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03802786 | Nov 2018 → Jul 2019 | — | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT03618316 | Jun → Jul 2018 | — | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT02924337 | Sep → Dec 2016 | PR interval, variation in | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT02373150 | Feb → Oct 2015 | type 2 diabetes mellitus | Poxel SA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01951235 | Jan 2013 → Jul 2014 | type 2 diabetes mellitus | Poxel SA | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07436182 | Mar → Jun 2026 overdue | — | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05366868 | May 2022 → Aug 2026 overdue | type 2 diabetes mellitus | National Center for Global Health and Medicine, Japan | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imeglimin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03618316 ↗ |
| Known as | EMD-387008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297514 ↗ |
| Known as | Imeglimina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297514 ↗ |
| Known as | Imeglimine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297514 ↗ |
| Known as | Twymeeg | “Imeglimin (Twymeeg)” NCT07436182 ↗ |
| Action | Activate | “enhances mitochondrial Complex I and III activity” NCT07436182 ↗ |
| Modality | Small molecule | — CHEMBL4297514 ↗ |
| Route | Oral | “Tablet, oral, single dose” NCT02924337 ↗ |